The VIVA‐MIND study: Topline Results from Phase 2 RCT of Varoglutamstat in Early AD
Varoglutamstat was safe and well-tolerated in this VIVA-MIND early AD RCT. Efficacy assessment did not demonstrate any significant treatment benefits however, the available sample was limited. Biomarker results and PK/PD are pending.
Authors
- Carolyn Revta
- Antje Meyer (ORCID: https://orcid.org/0000-0003-1675-4512)
- Howard Feldman (ORCID: https://orcid.org/0000-0002-9258-4538)
- Jody‐Lynn Lupo (ORCID: https://orcid.org/0000-0002-9323-5727)
- Natalie E. Quach (ORCID: https://orcid.org/0000-0001-9382-5826)
- Andrew MacKelfresh
- Karen Messer (ORCID: https://orcid.org/0000-0002-9298-2413)
- Steven D. Edland (ORCID: https://orcid.org/0000-0002-1153-7335)
- Christine Wenzkowski
- Gabriel C. Léger (ORCID: https://orcid.org/0000-0001-7900-3957)
- Frank U. Weber
- Tanja Wassmann
- Jasmin Duehring
- Michael Schaeffer
- Archana Balasubramanian
- Jing Zhang
- Nicola Lama
- ADCS VIVA‐MIND Study Group
- Sylvia Schell‐Mader
- Alessandra Pol
- Diane M. Jacobs
Institutions
- University of San Diego (US)
- University of California San Diego (US)
- Halle Zoo (DE)
- Alzheimer’s Disease Neuroimaging Initiative (US)
- European Organization for Nuclear Research (CH)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_105693
- Citations
- 1
- Primary Topic
- Neuroscience and Neuropharmacology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.91